Allelic variations in CYP2B6 and CYP2C19 and survival of patients receiving cyclophosphamide prior to myeloablative hematopoietic stem cell transplantation

Am J Hematol. 2010 Dec;85(12):967-71. doi: 10.1002/ajh.21889.

Authors

Stacy E F Melanson, Kristen Stevenson, Haesook Kim, Joseph H Antin, Michael H Court, Vincent T Ho, Jerome Ritz, Robert J Soiffer, Frank C Kuo, Janina A Longtine, Petr Jarolim

PMID: 21108329
DOI: 10.1002/ajh.21889

No abstract available

MeSH terms

Alleles
Aryl Hydrocarbon Hydroxylases / genetics*
Cyclophosphamide / metabolism
Cyclophosphamide / therapeutic use
Cyclophosphamide / toxicity*
Cytochrome P-450 CYP2B6
Cytochrome P-450 CYP2C19
Female
Genetic Variation*
Genotype
Hematologic Neoplasms / complications
Hematologic Neoplasms / therapy
Hematopoietic Stem Cell Transplantation / methods*
Hematopoietic Stem Cell Transplantation / mortality
Humans
Male
Middle Aged
Myeloablative Agonists / therapeutic use
Oxidoreductases, N-Demethylating / genetics*
Survival Analysis
Transplantation Conditioning / adverse effects
Transplantation Conditioning / mortality

Substances

Myeloablative Agonists
Cyclophosphamide
Aryl Hydrocarbon Hydroxylases
CYP2B6 protein, human
CYP2C19 protein, human
Cytochrome P-450 CYP2B6
Cytochrome P-450 CYP2C19
Oxidoreductases, N-Demethylating